title: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
abstract: OBJECTIVE
  Aromatase inhibitors (AIs) are now established as adjuvant therapy for early hormone receptor-positive breast cancer in postmenopausal women. Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances.
  
  
  METHODS
  The use of aromatase inhibitors as adjuvant therapy in younger women age > or = 40 with hormone receptor-positive early breast cancer and chemotherapy-induced amenorrhea has been audited clinically and biochemically. Results A total of 45 such women were identified in the audit, with a median age of 47 years (range, 39 to 52 years). Twelve women (27%) showed a return of ovarian function (10 renewed menses, one pregnancy, one biochemically premenopausal) after starting an AI. Median age at restart of ovarian function was 44 years (range, 40 to 50 years).
  
  
  CONCLUSIONS
  AIs may promote recovery of ovarian function in some women with chemotherapy-induced amenorrhea and should be used with caution. Biochemical monitoring of ovarian function requires highly sensitive immunoassays. Guidelines for the selection and delivery of adjuvant endocrine therapy in such patients are proposed.
authors.affiliation: Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom. ian.smith@rmh.nhs.uk
authors.forename: Ian E
authors.initials: IE
authors.lastname: Smith
authors.forename: Mitch
authors.initials: M
authors.lastname: Dowsett
authors.forename: Yoon-Sim
authors.initials: YS
authors.lastname: Yap
authors.forename: Geraldine
authors.initials: G
authors.lastname: Walsh
authors.forename: Per E
authors.initials: PE
authors.lastname: Lønning
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Santen
authors.forename: Daniel
authors.initials: D
authors.lastname: Hayes
mesh_terms: D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced*; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D000077289:Letrozole; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use; D010052:Ovariectomy; D017410:Practice Guidelines as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; C056516:exemestane